Cancer Generics Market Analysis

Share |

Publish Date: Sep, 2011

No. of Pages: 80

Format: Adobe Reader (PDF) Upto 24 hour delivery

	Electronic Access - Single User License		US$ 1000.00
	CD-ROM Mail Delivery		US$ 1100.00
	Hard Copy Mail Delivery		US$ 1100.00
	Electronic Access - Multi-User License		US$ 1400.00

Description

Table of Content

List of Figures & Tables

1. Analyst View

2. Research Methodology

3. Cancer Therapeutics Market

4. Market Drivers & Trends
     4.1 Higher Incidences of Cancer
     4.2 Oncology Therapeutics: Major Focus Area
     4.3 Alliances on the Rise
     4.4 Companies Thriving for New Generic Cancer Drugs

5. Generic Cancer Drugs: Market Overview

6. Oral Generic Cancer Drugs
     6.1 Arimidex (Anastrozole)
     6.2 Casodex (Bicalutamide)
     6.3 Aromasin (Exemestane)
     6.4 Femara (Letrozole)
     6.5 Leucovorin Calcium
     6.6 Megestrol Acetate
     6.7 Mercaptopurine
     6.8 Tarceva (Erlotinib)
     6.9 Tamoxifen
     6.10 Methotrexate
     6.11 Flutamide
     6.12 Hydrea (Hydroxyurea)

7. Generic Cancer Injectables
     7.1 Eligard (Leuprolide Acetate)
     7.2 Zoladex (Goserelin)
     7.3 Camptosar (Irinotecan)
     7.4 Zoledronic Acid
     7.5 Velcade (Bortezomib)
     7.6 Kytril (Granisetron)
     7.7 Taxotere (Docetaxel)
     7.8 Gemzar (Gemcitabine)

8. Pipeline Drugs

9. Key Players
     9.1 Teva
     9.2 Hospira
     9.3 Ranbaxy
     9.4 Cipla
     9.5 Natco Pharma
     9.6 Dr. Reddy’s

Not able to find data you are looking for? Ask our Research Analyst.